|
KMID : 1009020100080020111
|
|
Clinical Psychopharmacology and Neuroscience
2010 Volume.8 No. 2 p.111 ~ p.114
|
|
|
Ziprasidone for the Treatment of Delirium: Case Studies
|
|
Jung Sung-Won
|
|
|
Abstract
|
|
|
|
Delirium is common in hospitalized patients, and the gold standard for the control of its symptoms is haloperidol. Haloperidol, however, has some adverse effects, including extrapyramidal symptoms, which require limiting its use. Many studies have reported on the effectiveness of atypical antipsychotics such as aripiprazole, risperidone, olanzapine, and quetiapine for delirium, all of which have been found to be safe and effective alternatives to haloperidol. To our knowledge, only two reports have described the use of ziprasidone for treating delirium; such reports may be rare for several reasons, but the most likely one concerns its adverse effects. Although ziprasidone has the potential to cause dose-related QTc interval prolongation and is considered more likely to do so than several other antipsychotics, clinically significant prolongation of the QTc interval (generally defined as ＞500 ms) with recommended dosages of ziprasidone has been uncommon. Generally, checking the electrocardiogram regularly in patients without heart disease who take ziprasidone is thought to be unnecessary. We herein describe some patients with delirium who were treated with ziprasidone. A low rate of adverse effects was observed, and thus ziprasidone may be an appropriate for the treatment of delirium. A controlled comparison study should be performed to confirm this finding.
|
|
|
KEYWORD
|
|
|
Delirium, Ziprasidone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|